<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="732">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387292</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2020_12</org_study_id>
    <nct_id>NCT04387292</nct_id>
  </id_info>
  <brief_title>Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic</brief_title>
  <acronym>SOCOVID</acronym>
  <official_title>Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The
      ocular involvement is probably multiple, ranging from pathologies of the anterior segment
      such as conjunctivitis and anterior uveitis to disorders that threaten vision such as
      retinitis or optic neuropathy. On the other hand, in addition to this impairment, when
      patients are hospitalized for acute respiratory failure, complications related to possible
      resuscitation, medication prescriptions, positioning and oxygenation.

      COVID-19 itself, has several components:

        -  An apoptotic action of the viral attack which will generate cellular destruction,
           whether pulmonary, cardiac or renal or maybe ocular

        -  A secondary autoimmune action with the development of major vascular inflammation,
           possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary &quot;hyper&quot;
           inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is
           described in 3,7% to 4 ,3% of severe cases.

        -  A thromboembolic action
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients
      already discharged at the start of the study), patients will be informed of the study. An
      ophthalmology appointment will be given to them between 4 and 6 months after their discharge.

      During the ophthalmology appointment, the patient's clinical data will be collected during an
      interview (medical and treatment history, blood group). The patient will benefit from a full
      ophthalmological examination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the ophthalmological problems observed</measure>
    <time_frame>6 months after discharge of hospitalization</time_frame>
    <description>Multimodal ophthalmologic imaging</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID19</condition>
  <condition>Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmologic exam</intervention_name>
    <description>Visual acuity (ETDRS exam)
Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test
Lipiview
Eye pressure measurement (air tonometer)
Wide field retinophotography
Multicolor and auto-fluorescence retinophotography
Indocyanine green retinal angiography
Optical coherence tomography (OCT) B posterior pole scan
OCT Angiography (OCT-A) of the optic nerve and posterior pole
Adaptive optics
Visual field (Humphrey)</description>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or
             PCR- Polymerase chain reaction)

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine MAUGET FAYSSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Am√©lie YACHITZ, MD</last_name>
    <phone>(0)148036454</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivien VASSEUR</last_name>
    <phone>(0)148036440</phone>
    <phone_ext>+33</phone_ext>
    <email>vvasseur@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine MAUGET FAYSSE, MD</last_name>
      <phone>(0)148036437</phone>
      <phone_ext>+33</phone_ext>
      <email>mmfaysse@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

